Practical Consensus Guidelines for the Use of S-1 in GI Malignancies

Abstract

Purvish M Parikh

S-1 (5-fluorouracil prodrug [tegafur] in combination with 5-chloro-2,4-dihydroxypyridine [CDHP] and potassium oxonate [OXO]) was first approved in 1999. In order to make it easy for community oncologists, we decided to put together this expert consensus guideline for its use in gastrointestinal (GI) malignancies. A total of 15 subject matter experts used modified Delphi method to discuss, analyze, and vote on key aspects regarding practical approach to use of S-1 in GI cancers, a process involving 6 months of work. The consensus guidelines specify how S-1 use can be optimized in patients with colorectal, gastric, and pancreatic tumors. The voting for the 17 key points resulted in a majority consensus for all the statements (approval ranging from 13/15 [87%] to 15/15 [100%]). S-1 is a combination of three drugs (tegafur, CDHP, and OXO) specifically designed to reduce toxicity and enhance efficacy; clinical data and meta-analysis confirm both factors; and it is recommended as standard of care for GI cancers. S-1 is approved and one of the standards of care for all lines of therapy in colorectal cancer and pancreatic cancers. S-1 with oxaliplatin is the standard of care for gastric cancers.

Keywords

SCOPE-C - IASCO - Tegafur - OXO - CDHP - SAARC

Publikationsverlauf

Artikel online veröffentlicht:
05. Februar 2024

• References

• 1 Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs 2009; 18 (03) 335-348
• 2 Haller DG, Cassidy J, Clarke SJ. et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26 (13) 2118-2123
• 3 Kobayakawa M, Kojima Y. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoTargets Ther 2011; 4: 193-201
• 4 Parikh P, Babu G, Singh R. et al. Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method. BMC Cancer 2023; 23 (01) 714
• 5 Parikh PM, Prabhash K, Arora B, Mistry K. Promoting of Oncology Training and Education in India: lessons from our unique oncology continuing medical education project. Indian J Med Paediatr Oncol 2014; 35 (02) 175
• 6 https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/incidence
• 7 https://gco.iarc.fr/today/fact-sheets-cancers
• 8 Deo SVS, Kumar S, Bhoriwal S. et al. Colorectal cancers in low- and middle-income countries-demographic pattern and clinical profile of 970 patients treated at a tertiary care cancer center in India. JCO Glob Oncol 2021; 7: 1110-1115
• 9 Pathy S, Lambert R, Sauvaget C, Sankaranarayanan R. The incidence and survival rates of colorectal cancer in India remain low compared with rising rates in East Asia. Dis Colon Rectum 2012; 55 (08) 900-906
• 10 GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol 2022; 7 (07) 627-647 Erratum in: Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. PMID: 35397795; PMCID: PMC9192760
• 11 Schlesinger-Raab A, Werner J, Friess H, Hölzel D, Engel J. Age and outcome in gastrointestinal cancers: a population-based evaluation of oesophageal, gastric and colorectal cancer. Visc Med 2017; 33 (04) 245-253
• 12 Parikh PM, Chaitanya K, Boppana M, Kumar MS, Shankar K. Geriatric oncology landscape in India – current scenario and future projections. Cancer Research, Statistics, and Treatment 2020; 3 (02) 296-299
• 13 Banerjee J, Satapathy S, Upadhyay AD. et al. A short geriatric assessment tool for the older person with cancer in India-Development and psychometric validation. J Geriatr Oncol 2019; 10 (02) 222-228
• 14 Parikh PM, Raja T, Mula-Hussain L. et al. Afro Middle East Asian symposium on cancer cooperation. South Asian J Cancer 2014; 3 (02) 128-131
• 15 Parikh PM, Mullapally SK, Hingmire S. et al. Cervical cancer in SAARC countries. South Asian J Cancer 2023; 12 (01) 1-8
• 16 Pathi N, Parikh PM, Banerjee J, Tilak T, Prem NN, Pillai A. Unmet Needs in Geriatric Oncology. South Asian J Cancer 2023; Aug 7; 12 (02) 221-227
• 17 Chhetri P, Giri A, Shakya S, Shakya S, Sapkota B, Pramod KC. Current development of anti-cancer drug S-1. J Clin Diagn Res 2016; 10 (11) XE01-XE05
• 18 Matt P, van Zwieten-Boot B, Calvo Rojas G. et al. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). Oncologist 2011; 16 (10) 1451-1457
• 19 Muro K, Boku N, Shimada Y. et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11 (09) 853-860
• 20 Park SH, Lim DH, Sohn TS. et al; ARTIST 2 investigators. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial^☆ . Ann Oncol 2021; 32 (03) 368-374
• 21 Park YS, Lim HY, Kim TW. et al. A randomized phase III study of SOX (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer. JCO 2011; 29 (15_suppl): 3524
• 22 Kwakman JJM, Simkens LHJ, van Rooijen JM. et al. Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol 2017; 28 (06) 1288-1293
• 23 Denda T, Takashima A, Gamoh M. et al. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. Eur J Cancer 2021; 154: 296-306
• 24 Nishizawa Y, Haraguchi N, Kim H. et al. Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). BMC Cancer 2021; 21 (01) 947
• 25 Yoshida M, Ishiguro M, Ikejiri K. et al; ACTS-CC study group. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol 2014; 25 (09) 1743-1749
• 26 Winther SB, Österlund P, Berglund Å. et al; - on behalf of the Academy of Geriatric Cancer Research (AgeCare). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer 2017; 17 (01) 548
• 27 Yoshida M, Muro K, Tsuji A. et al. Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer 2015; 51 (08) 935-941
• 28 Yoshino T, Arnold D, Taniguchi H. et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 2018; 29 (01) 44-70
• 29 Feng Z, Yan P, Hou X, Feng J, He X, Yang K. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials. Ann Palliat Med 2020; 9 (03) 883-894
• 30 Yang J, Zhou Y, Min K, Yao Q, Xu CN. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis. World J Gastroenterol 2014; 20 (33) 11886-11893
• 31 Lee CM, Yoo MW, Son YG. et al. Long-term efficacy of S-1 monotherapy or capecitabine plus oxaliplatin as adjuvant chemotherapy for patients with stage II or III gastric cancer after curative gastrectomy: a propensity score-matched multicenter cohort study. J Gastric Cancer 2020; 20 (02) 152-164
• 32 Choi S, Min J-S, Jeong S-H. et al. Long-term survival outcomes of elderly patients treated with S-1 or capecitabine plus oxaliplatin for stage II or III gastric cancer: a multicenter cohort study. J Gastric Cancer 2022; 22 (01) 67-77
• 33 Xu R, He X, Wufuli R. et al. Choice of capecitabine or S1 in combination with oxaliplatin based on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression status in patients with advanced gastric cancer. J Gastric Cancer 2019; 19 (04) 408-416
• 34 Yamada Y, Higuchi K, Nishikawa K. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 2015; 26 (01) 141-148
• 35 Maeda A, Boku N, Fukutomi A. et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol 2008; 38 (03) 227-229
• 36 Okusaka T, Nakamura M, Yoshida M. et al; Committee for Revision of Clinical Guidelines for Pancreatic Cancer of the Japan Pancreas Society. Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas 2020; 49 (03) 326-335
• 37 Groen JV, Douwes TA, van Eycken E. et al; Dutch Pancreatic Cancer Group. Treatment and survival of elderly patients with stage I-II pancreatic cancer: a report of the EURECCA pancreas consortium. Ann Surg Oncol 2020; 27 (13) 5337-5346
• 38 Henry AC, Schouten TJ, Daamen LA. et al; Dutch Pancreatic Cancer Group. Short- and long-term outcomes of pancreatic cancer resection in elderly patients: a nationwide analysis. Ann Surg Oncol 2022; 29 (09) 6031-6042
• 39 https://en.wikipedia.org/wiki/Criticism_of_the_Food_and_Drug_Administration
• 40 https://www.practiceupdate.com/content/nccn-recommends-new-drugs-beyond-fda-approved-indications/65228
• 41 McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol 1996; 41 (05) 425-427
• 42 McLeod HL, Milne LH, Johnston SJ. 5-Fluorouracil metabolizing enzymes. Methods Mol Med 1999; 28: 111-120
• 43 Miura K, Shirasaka T, Yamaue H, Sasaki I. S-1 as a core anticancer fluoropyrimidine agent. Expert Opin Drug Deliv 2012; 9 (03) 273-286
• 44 Chelakkot PG, Ravind R, Sruthi K, Menon D. Treatment in resectable non-metastatic adenocarcinoma of stomach: changing paradigms. Indian J Cancer 2019; 56 (01) 74-80
• 45 Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev 2018; 4 (04) CD011746
• 46 Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L. Current and emerging therapeutic approaches for colorectal cancer: a comprehensive review. World J Gastrointest Surg 2023; 15 (04) 495-519
• 47 Pallet N, Hamdane S, Garinet S. et al. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer 2020; 123 (05) 811-818
• 48 Sahu A, Ramaswamy A, Ostwal V. Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience. J Gastrointest Oncol 2016; 7 (03) 380-386
• 49 Martens FK, Huntjens DW, Rigter T, Bartels M, Bet PM, Cornel MC. DPD testing before treatment with fluoropyrimidines in the Amsterdam UMCs: an evaluation of current pharmacogenetic practice. Front Pharmacol 2020; 10: 1609
• 50 Deboever G, Hiltrop N, Cool M, Lambrecht G. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. Clin Colorectal Cancer 2013; 12 (01) 8-14